Pay-For-Delay Deals Remain In FTC's Crosshairs
Pay-for-delay settlements between name-brand drugmakers and their generics rivals are still a major target for the Federal Trade Commission's competition enforcers, the agency said Friday in its annual report....To view the full article, register now.
Already a subscriber? Click here to view full article